🧪
hypothesis

APOE4-associated inflammatory signaling amplifies SREBP2 activity in glia independently of primary sterol sensing defects

Hypothesis

APOE4-associated inflammatory signaling amplifies SREBP2 activity in glia independently of primary sterol sensing defects

A modifier model is that APOE4 reactive-state signaling, potentially through NF-kB or mTORC1-linked programs, increases SREBP2 activity even when sterol trafficking is not the sole lesion.
🧬 SREBF2🩺 molecular-biology🎯 Composite 47%💱 $0.50▲6.1%proposed
molecular biology
EvidencePending (0%)📖 0 cit🗣 1 debates 7 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.55 (15%) Evidence 0.46 (15%) Novelty 0.61 (12%) Feasibility 0.66 (12%) Impact 0.40 (12%) Druggability 0.33 (10%) Safety 0.24 (8%) Competition 0.51 (6%) Data Avail. 0.49 (5%) Reproducible 0.44 (5%) KG Connect 0.50 (8%) 0.470 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite47%

🧪 Overview

A modifier model is that APOE4 reactive-state signaling, potentially through NF-kB or mTORC1-linked programs, increases SREBP2 activity even when sterol trafficking is not the sole lesion. This is best treated as an amplifier or combination axis rather than the primary explanation for SCAP-SREBP2 dysregulation.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["APOE4 Reactive Glial State<br/>Astrocyte and Microglia"]
    B["NF-kB Pathway Activation<br/>Inflammatory transcription"]
    C["mTORC1 Signaling<br/>Nutrient sensing dysregulation"]
    D["SCAP Conformational Change<br/>Escort protein activation"]
    E["SREBF2/SREBP2 Processing<br/>Sterol regulatory element binding"]
    F["Cholesterol Biosynthesis<br/>Gene Upregulation"]
    G["Glial Cholesterol<br/>Dyshomeostasis"]
    H["Neuronal Lipid<br/>Support Failure"]
    A --> B
    A --> C
    B --> D
    C --> D
    D --> E
    E --> F
    F --> G
    G --> H
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix7 supports3 contradicts
Supports
Inflammatory signaling can alter accessible cholesterol and activate canonical SCAP-SREBP processing in other systems.
PMID:35959888
Supports
APOE4 glia commonly exhibit reactive inflammatory phenotypes that could potentiate SREBP2 output.
PMID:37995685
Supports
Tonic prime-boost of STING signalling mediates Niemann-Pick disease type C.
Nature2021PMID:34290407
Supports
25-Hydroxycholesterol attenuates tumor necrosis factor alpha-induced blood-brain barrier breakdown in vitro.
Biochim Biophys Acta Mol Basis Dis2024PMID:39181516
Supports
Relationships of brain cholesterol and cholesterol biosynthetic enzymes to Alzheimer's pathology and dementia in the CFAS population-derived neuropathology cohort.
Neurosci Res2024PMID:38278219
Supports
Neuronal Cholesterol Deficiency Mediated by Astrocytic SREBP2 Downregulation Leads to Postoperative Cognitive Dysfunction Through Impairment of Hippocampal Synaptic Plasticity and Excitatory Synaptic Transmission.
Adv Sci (Weinh)2026PMID:41674341
Supports
Localization of the transcription factor, sterol regulatory element binding protein-2 (SREBP-2) in the normal rat brain and changes after kainate-induced excitotoxic injury.
J Chem Neuroanat2009PMID:19124072
Contradicts
There is no clean demonstration of an APOE4-to-NF-kB/mTORC1-to-SREBP2 pathway in astrocytes or microglia.
PMID:37995685
Contradicts
Inflammation may be downstream of lipid dyshomeostasis rather than the initiating cause of SREBP2 activation.
PMID:35750033
Contradicts
NF-kB and mTORC1 are broad, toxicity-prone targets with poor standalone trial readiness in neurodegeneration.
PMID:35959888
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — SREBF2

No curated PDB or AlphaFold mapping for SREBF2 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SREBF2 from GTEx v10.

Cerebellum161 Cerebellar Hemisphere147 Cortex108 Frontal Cortex BA9107 Anterior cingulate cortex BA2487.7 Amygdala65.5 Hypothalamus61.1 Nucleus accumbens basal ganglia59.4 Hippocampus57.2median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SREBF2 →

No DepMap CRISPR Chronos data found for SREBF2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0108
Events (7d)
1
Price History
▲6.1%

💾 Resource Usage

LLM Tokens
17,104
$0.0513
Total Cost
$0.0513

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF NF-κB signaling is pharmacologically inhibited with IKKβ inhibitor (BAY 11-7082, 5 μM) in APOE4/4 human iPSC-derived astrocytes, THEN SREBP2 nuclear protein levels and downstream target gene expresSREBP2 activity marker decrease (nuclear translocation and target transcription)— no observation —pending0.70
IF APOE4/4 and APOE3/3 primary mouse astrocytes (human APOE knock-in) are treated with IL-1β (10 ng/mL) for 6 hours, THEN SREBP2 nuclear localization and cholesterol biosynthesis gene expression will Genotype-stratified SREBP2 activation difference favoring APOE4 under inflammatory conditions— no observation —pending0.65
🔮 Falsifiable Predictions (2)
pendingconf 70%
IF NF-κB signaling is pharmacologically inhibited with IKKβ inhibitor (BAY 11-7082, 5 μM) in APOE4/4 human iPSC-derived astrocytes, THEN SREBP2 nuclear protein levels and downstream target gene expression (HMGCR, LDLR, FASN) will decrease by >40% within 24 hours compared to vehicle-treated APOE4/4 c
Predicted outcome: SREBP2 activity marker decrease (nuclear translocation and target transcription)
Falsification: SREBP2 target gene expression and nuclear protein levels remain unchanged or increase despite NF-κB inhibition, indicating the APOE4 amplification effect operates independently of NF-κB signaling.
pendingconf 65%
IF APOE4/4 and APOE3/3 primary mouse astrocytes (human APOE knock-in) are treated with IL-1β (10 ng/mL) for 6 hours, THEN SREBP2 nuclear localization and cholesterol biosynthesis gene expression will be significantly elevated (p<0.05) in APOE4/4 versus APOE3/3 cells, with the fold-difference exceedi
Predicted outcome: Genotype-stratified SREBP2 activation difference favoring APOE4 under inflammatory conditions
Falsification: No significant difference in SREBP2 activity between APOE genotypes under IL-1β treatment, or the difference is identical to/less than that observed under sterol sensing manipulation, disproving the s
View on SciDEX ↗